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ABSTRACT
Objectives To investigate the impact of harm-reduction programmes on HIV and hepatitis C virus (HCV) incidence
among ever-injecting drug users (DU) from the Amsterdam Cohort Studies (ACS). Methods The association between
use of harm reduction and seroconversion for human immunodeﬁciency virus (HIV) and/or hepatitis C virus (HCV)
was evaluated using Poisson regression. A total of 714 DU were at risk for HIV and/or HCV during follow-up. Harm
reduction was measured by combining its two most important components—methadone dose and needle exchange
programme (NEP) use—and looking at ﬁve categories of participation, ranging from no participation (no methadone
in the past 6 months, injecting drug use in the past 6 months and no use of NEP) to full participation ( 60 mg
methadone/day and no current injecting or  60 mg methadone/day and current injecting but all needles
exchanged). Results Methadone dose or NEP use alone were not associated signiﬁcantly with HIV or HCV serocon-
version. However, with combination of these variables and after correction for possibly confounding variables, we
found that full participation in a harm reduction programme (HRP) was associated with a lower risk of HIV and HCV
infectioninever-injectingdrugusers(DU),comparedtonoparticipation[incidencerateratio0.43(95%CI0.21–0.87)
and 0.36 (95% CI 0.13–1.03), respectively]. Conclusions In conclusion, we found that full participation in HRP was
associated with a lower incidence of HCV and HIV infection in ever-injecting DU, indicating that combined prevention
measures—but not the use of NEP or methadone alone—might contribute to the reduction of the spread of these
infections.
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INTRODUCTION
Injecting drug users (DU) are at high risk from blood-
borne infections, including human immunodeﬁcency
virus (HIV) and hepatitis C virus (HCV), through the
sharing of needles and injection equipment [1]. Various
approaches to deal with the consequences of hard drugs
havebeentaken;somecountriesaimtobanillicitdruguse
completely, whereas the Netherlands and others take a
harmreductionapproach.Thisharmreductionapproach
may have had a major impact on the HIV and HCV epi-
demic.The ultimate goal of harm reduction is to stop DU
from using drugs, but until this is possible the policy is to
minimize the damage DU inﬂict upon themselves and the
societyatlarge.Diverseprogrammes(withalow,medium
or high threshold) [2] started in the Netherlands at the
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with social–medical care and needle-exchange facilities.
They have no waiting lists and are relatively easy to enter
and re-enter. Ongoing drug use during participation is
tolerated in low- and medium-threshold programmes.
Low-threshold programmes have been operated since
1982 by the Amsterdam Health Service. For clients who
have regulated their drug use, methadone can be pre-
scribed in a medium-threshold programme via their
general practitioner. Clients who are willing to detoxify
can receive methadone in a high-threshold programme
through an out-patient addiction clinic. Circulation
between the different programmes is permitted and ‘pro-
motion’ to higher-threshold programmes is encouraged.
With the harm reduction approach, the Amsterdam
methadone programmes reached an estimated 2700 of
the 3500–4000 opiate users in Amsterdam [3]. All ser-
vices are free of charge for residents of the Netherlands.
The effects of methadone provision or needle
exchange programmes (NEP) separately on HIV inci-
dence have been examined, with conﬂicting results [4,5].
Very few studies describe the effect of either programme
onHCVincidence,althoughdecliningprevalenceof HCV
was reported after the introduction of NEP [6].
The Amsterdam Cohort Study (ACS) among drug
users comprises a large group of DU who are tested pro-
spectively for HIV. We tested their stored sera for HCV,
retrospectively,andthereforehadtheuniqueopportunity
to document the effect of harm reduction on the inci-
denceof bothHIVandHCVoveralongtimeperiod[7–9].
MATERIALS AND METHODS
Study population and design
The Amsterdam Cohort Study (ACS) among DU is an
open, prospective cohort study initiated to investigate the
prevalence, incidence and risk factors of infections with
HIV-1andotherblood-borneand/orsexuallytransmitted
infections, as well as the effects of interventions [10]. It
has collected detailed information on participation in
harm reduction programmes (HRPs).The DU cohort was
initiated in 1985; recruitment is ongoing and in recent
years has been directed in particular towards young DU.
ACS participation is voluntary, and informed consent
is obtained for every participant at intake. ACS partici-
pants visit the Amsterdam Health Service every
4–6 months.Atintakeandeveryvisit,theygivebloodfor
HIV testing and storage; they also complete a standard-
ized questionnaire about their health, drug use and
sexual risk behaviour and socio-demographic situation.
At intake, questions about current behaviour refer to the
preceding 6 months and/or to the period since 1980 or
since the start of regular use of hard drugs (i.e. heroin,
cocaine, amphetamines and/or methadone at least three
times per week). At follow-up visits, questions refer to the
time between the present and the preceding visit.
Laboratory methods
All ACS participants since 1985 (n = 1640) were tested
prospectively for HIV antibodies by enzyme-linked immu-
nosorbent assays (ELISA). All participants with at least
two visits between December 1985 and November 2005
(n = 1276) were tested retrospectively for HCV antibod-
ies, using the ﬁrst sample available in each case. Third-
generation ELISA tests were used to detect HCV
antibodies (AxSym HCV version 3.0; Abbott, Wiesbaden,
Germany). Individuals who were HCV-negative at ACS
entry were tested for HCV antibodies at their most recent
ACS visit. On ﬁnding HCV seroconversion (deﬁned as the
presence of HCV antibodies in a previously seronegative
individual), we tested samples taken between these two
visits to indicate the seroconversion interval.
Statistical analyses
HIV- and/or HCV-negative ever-injecting drug users
entered the risk set at study entry or at their start of
injecting drug use during follow-up, and were
followed-up until seroconversion for, respectively, HIV or
HCV, or until end of follow up, ultimately at 1 November
2005. The date of HCV or HIV seroconversion was esti-
mated as the midpoint between the last seronegative and
the ﬁrst seropositive ACS visit. Poisson regression was
used to determine the effect of harm reduction on HCV
and HIV incidence. Incidence rates and incidence rate
ratios (IRR) with their corresponding 95% conﬁdence
intervals (95% CI) were calculated. We evaluated the
potential confounding effect of all variables listed below
and evaluated interaction between variables included in
the ﬁnal model. Multivariate models were built using
forward-stepwise techniques, and variables with a
univariate P-value  0.10 were considered as potential
independent determinants. All variables subject to
change were treated as time-dependent variables. A
P-value  0.05 was considered statistically signiﬁcant.
To study the impact of harm reduction on HIV and
HCV seroconversion, we combined injecting drug use,
use of NEP and methadone dosage into one variable with
ﬁve categories (Table 1). Because higher doses of metha-
done are more effective than lower doses in lowering the
prevalence of injecting drug use risk behaviour, we con-
sidered  60 mg methadone per day an adequate
minimum dosage for opioid replacement therapy and
used that dose as cut-off value for our deﬁnition of
adequate harm reduction [11–13].
General characteristics of persons evaluated included
sex,nationality,age,HIVstatusforHCVasoutcome,HCV
status for HIV as outcome, HIV status of the steady
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variables included current injecting (yes or no), fre-
quency of injecting, main type of drug injected, time
elapsed since start of injecting drug use, frequency of
non-injecting drug use and type of drug used mainly as
non-injecting drug.
RESULTS
General characteristics
Intotal,1640 DUwereenrolledintheACS;1276 DUhad
at least two visits. DU with more than one visit were older
[median 31.4 (interquartile range (IQR) 31.0–31.8)
years versus 28.7 (IQR 28.1–29.4) years], more often
male (63.9% versus 56.9%), more often of Dutch nation-
ality (74.5% versus 60.2%) and more often HIV-positive
(20.6% versus 16.2%) when compared to DU with only
one visit to the ACS.
A total of 952 DU were so-called ever-injecting DU:
DU who had ever injected drugs before ACS entry
(n = 905)orwhostartedinjectingdrugsduringfollow-up
(n = 47). Of these ever-injecting DU, 714 were HIV-
and/or HCV-negative at study entry and were at risk for
HIV and/or HCV during follow-up. One hundred and
sixty-four DU (22.9%) were negative for both infections
at study entry, 546 DU (76.5%) were HIV-negative and
HCV-positive and four DU (0.6%) were HCV-negative and
HIV-positive. The HIV prevalence among HCV-negative
DU was 2.4% at entry, while the HCV prevalence among
HIV-negative DU was much higher (76.2%). The DU
included were mainly of Dutch nationality and mainly
male (Table 2).
HIV-negativeDUhadalongermediantimesincestart-
inginjectionthanHCV-negativeDU(respectively,7.4and
2.4 years). Furthermore, the proportion of DU who had
recently injected (i.e. in the past 6 months before ACS
entry) was larger for the HIV-negative DU than for HCV-
negative DU. HIV-negative DU injected more often than
HCV-negative DU, and HCV-negative DU used non-
injecting drugs more often than their HIV-negative coun-
terparts (Table 2). The median follow-up time was
3.56 years (IQR 1.15–7.91 years) for DU at risk for HCV
and 8.13 years (IQR 4.25–13.0 years) for DU at risk for
HIV.
Under study, 90 of 710 DU at risk for HIV serocon-
verted and 58 of 168 at risk for HCV. The median dura-
tionof theHIVandHCVseroconversionintervalbetween
visits was 4.0 months (IQR 3.7–6.0 months) and
4.0 months (IQR 3.7–5.1 months), respectively. The HIV
incidence ranged from 8.5 per 100 person-years (PY) in
the late 1980s to approximately 0 in the most recent
years, whereas HCV incidence was very high in the late
1980s (27.5 per 100 PY) and declined to around two per
100 PY in more recent years [14].
Effect of harm reduction participation on HIV and
HCV incidence
When evaluating the separate effects on HIV and HCV
seroconversion of methadone dose or NEP we found
that having any prescribed dose of methadone was asso-
ciated with lower incidence rates of HIV and HCV infec-
tion, but not to a statistically signiﬁcant degree
(P = 0.084 and P = 0.21, respectively). Use of NEP was
associated with a higher risk of HIV and HCV serocon-
version but, with restriction of this analysis to injecting
drug use in the preceding 6 months, the IRR changed
towards one and no longer reached statistical signiﬁ-
cance (data not shown). However, when methadone
dose and NEP were combined as described in Table 1,
full participation in an HRP was associated with a two-
to threefold reduction in the risk of HIV seroconversion
and with a six- to sevenfold reduction in the risk of HCV
seroconversion (Table 3).
Table 1 Deﬁnitionof ﬁvelevelsof harmreductionusedtoevalu-
atetheeffectof harmreductiononHIVandHCVincidenceinthe
Amsterdam Cohort Studies.
No harm reduction No methadone in the past
6 months, injecting drug use
in the past 6 months, and no
use of NEP
Incomplete harm reduction Any dose of methadone daily in
the past 6 months, injecting
drug use in the past
6 months and irregular* or
no use of NEP; OR 0–59 mg
methadone daily in the past
6 months, injecting drug use
in the past
6 months, and always use†
of NEP
Full harm reduction  60 mg methadone daily in
the past 6 months and no
injecting drug use in the past
6 months; OR  60 mg
methadone daily, injecting
drug use in the past
6 months, and always use†
of NEP
Limited dependence on harm
reduction
1–59 mg methadone daily in
the past 6 months and no
injecting drug use in the past
6 months
No dependence on harm
reduction
No methadone in the past
6 months and no injecting
drug use in the past
6 months
*Irregular use of NEP = 1–99% of needles used in the past 6 months
obtained via NEP. †Always use of NEP = 100% of needles used in past
6 months obtained via NEP.
1456 Charlotte van den Berg et al.
© 2007 Amsterdam Health Service Addiction, 102, 1454–1462Table 2 Generalcharacteristicsatentryandduringfollow-upof 710HIV-negativeand168HCV-negativeever-injectingDUincluded
in HIV and HCV analyses, respectively.
HIV HCV
At entry
HIV/HCV infection (n at risk) 710 % 168 %
Prevalence HIV infection at
entry risk set
–4 2 . 4
Prevalence HCV infection at
entry risk set
541 76.2 –
Overall HIV incidence
(per 100 PY)
1.65
Overall HCV incidence
(per 100 PY)
6.78
General characteristics
Steady partner at entry 333 46.9 77 45.8
Median age at entry risk set
(years; IQR)
30.0 (27.0–36.0) 29.0 (25.0–33.0)
Female 274 38.6 56 33.3
Dutch nationality 526 74.1 147 87.5
Western European ethnicity 602 84.8 139 82.7
Injecting drug use
Median time since start
injecting (years; IQR)
7.21 (3.04–12.1) 2.43 (0.06–7.16)
Injecting in the past
6 months
524 73.8 100 59.5
Among recent injectors
injecting more than once a
week
429 82.3 53 54.6
Main drug injected
Heroin 94 17.9 33 33.0
Cocaine 77 14.7 14 14.0
Speedball (i.e. combination
of heroin and cocaine)
other
271
82
51.7
15.6
37
16
37.0
16.0
Non-injecting drug use
Non-injecting drug use in the
past 6 months
497 70.0 149 88.7
Frequency of non-injecting drug use
Once or more times daily 190 38.2 77 51.7
Once or more times weekly,
but less than once
or more times daily
188 37.8 61 41.0
Less than weekly 119 23.9 11 7.4
Main non-injecting drug use at entry
Heroin 239 48.2 66 44.2
Cocaine 215 43.3 73 49.0
Other 42 8.5 10 6.7
Follow-up
Median number of visits at risk
(IQR)
17 (8–29) 15 (8–28)
Median number of PY (IQR) 8.13 (4.25–13.0) 3.56 (1.15–7.91)
Median number of days
between follow up visits
(IQR)
128 (118–168) 128 (119–166)
PY = person years; IQR = interquartile range.
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© 2007 Amsterdam Health Service Addiction, 102, 1454–1462In univariate analysis the following variables were
alsoassociatedwithahigherriskof HIVorHCV:injecting
drug use in the past 6 months, borrowing needles in the
past 6 months, more recent onset of injecting drug use, a
higher frequency of injecting drugs, mainly injecting
speedball,youngerageandhavinganHIV-positivesteady
partner. A change in methadone dosage in the past
6 months was associated with a higher risk for HCV sero-
conversion but not HIV seroconversion. DU who were
chronically HIV-infected or had an acute HIV infection in
the6 monthsprecedingthevisitwereatincreasedriskfor
HCV seroconversion (Table 3).
Inmultivariateanalysiswefoundthataftercorrecting
for having an HIV-positive steady partner and a smaller
number of years since starting injection (both factors
being associated independently with HIV seroconver-
sion), the combined harm reduction variable remained
associated independently with HIV seroconversion
(Table 4).Thatis,DUfullyparticipatinginHRPswereata
decreasedriskof HIVseroconversioncomparedtoDUnot
participating fully in an HRP (IRR 0.43, 95% CI 0.21–
0.87).
In multivariate analysis for HCV, we found that with
correction for time elapsed since start of injecting, DU
participating fully in an HRP were at decreased risk of
HCV seroconversion compared to DU not participating in
an HRP (IRR 0.36, 95% CI 0.13–1.03). As with HIV, DU
who recently started injecting drug use were at increased
risk of HCV seroconversion. The effect of HIV status of
the steady partner on HCV incidence had the same direc-
tion as its effect on HIV incidence (Table 4).
In sensitivity analyses, we found that the effects of
harm reduction on HIV and HCV seroconversion did not
change substantially when analysis was restricted to the
years after 1989 (i.e. when a methadone dose of
 60 mg daily was more readily available for DU). Also,
when the lower limit of adequate methadone dosage was
adjusted to  80 mg daily, the effects of harm reduction
on HIV and HCV seroconversion did not change substan-
tially.
DISCUSSION
Our data suggest that the combination of adequate
methadonetherapyandfullparticipationinNEPcontrib-
uted substantially to the reduction of the incidence of
HIV and HCV in DU in Amsterdam, although a statisti-
cally signiﬁcant effect was not seen when methadone
dose or NEP were considered separately. It is likely that
Amsterdam’s comprehensive programme, in which
methadone treatment and NEP are combined, explains
the reported decline of HIV and HCV incidence.
We found no evidence that the effect of harm reduc-
tion was larger on HCV incidence than on HIV incidence,
as our risk estimates for the different levels of harm
reduction participation were comparable. One explana-
tion might be that the Amsterdam harm reduction
approach, which maintains contact with as many DU as
possible, has an effect not only on injecting but also on
sexualriskbehaviourduetocounsellingandcondomdis-
tribution. Our ﬁndings are in line with the reduction of
sexual and drug-related risk behaviour seen in the ACS
since the mid-1990s [7]. Having an HIV-positive steady
partner was associated with a higher risk of HIV infec-
tion,showingthatHIVissexuallytransmittedmoreeffec-
tively than HCV.
The evaluation of HRPs is complicated because it is
difﬁcult to link participation in HRPs to outcome vari-
Table 4 Multivariate analysis of the effect of participation in harm reduction programmes on HIV and HCV seroconversion.
HIV HCV
IRR 95% CI P-value IRR 95% CI P-value
Level of harm reduction (deﬁnitions described in Table 1)
No harm reduction 1 < 0.001 1 < 0.001
Incomplete harm reduction 0.87 0.50–1.52 1.17 0.59–2.31
Full harm reduction 0.43 0.21–0.87 0.36 0.13–1.03
Limited dependence on harm reduction 0.046 0.006–0.35 0.044 0.006–0.35
No dependence on harm reduction 0.20 0.078–0.50 0.13 0.044–0.40
Time since start injection drug use (per year) 0.95 0.92–0.98 < 0.001 0.87 0.81–0.93 < 0.001
HIV status of steady partner
No steady partner 1 0.004 1 0.026
HIV-positive steady partner 4.53 2.23–9.21 3.49 0.84–14.5
HIV-negative steady partner 0.82 0.43–1.57 0.42 0.13–1.37
Steady partner with unknown HIV status 0.75 0.18–3.06
IRR = incidence rate ratio, 95% CI = 95% conﬁdence interval.
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© 2007 Amsterdam Health Service Addiction, 102, 1454–1462ables, such as the incidence of blood-borne infections. In
someobservationalstudies,methadoneprogrammesand
NEP have been shown to reduce the incidence of HIV but
not HCV [5,6,15,16]. Ecological studies have shown a
declining HCV prevalence after the introduction of NEP
[17–20],whileHCVincidenceremainedhigh.Toourbest
knowledge, our study is the ﬁrst that describes the com-
bined effect of methadone therapy and NEP on HCV inci-
dence, and over the longest period of time. The ACS
among DU is a well-deﬁned open cohort study, with
ongoingrecruitment,thathasbeenfollowedoverthepast
20 years.Onaverage,90%of participantsthatvisitedthe
ACS a given calendar year returned the next year as well.
Despite its great strengths, ACS is not a randomized con-
trolled trial and therefore a causal association between
harm reduction participation and risk for HIV or HCV
infection cannot be proved. However, we could not think
of any unmeasured confounder both affecting harm
reduction participation and HIV or HCV infection.
Although NEP and methadone prescription were not
available at the study setting, we cannot exclude that a
cohort effect might explain partially the observed
decrease in HIV and HCV incidence and injecting behav-
iour we observed in our cohort. Furthermore, risk behav-
iour was self-reported, and bias toward socially desirable
answers could cause underestimation of the proportion
engaged in risk behaviour. Although the data on HRP
participation were also self-reported, Langendam et al.
studied the harm reduction measures in the ACS and
matchedtheself-reportedmethadonedosestothecentral
methadoneregistry(CMR)andtheyfoundnocleardiffer-
ence in the self-reported dose and the dose at the CMR
[21].
As expected, DU not injecting drugs in the past
6 months and taking a low dose of methadone daily (i.e.
with limited dependence on harm reduction) and DU not
injecting drugs in the past 6 months and not receiv-
ing any methadone (i.e. with no dependence on harm
reduction) were at lower risk for HIV and HCV serocon-
versionthanwereDUfullyparticipatinginanHRP.Inter-
estingly, the limited-dependence group were at lower risk
forHIVandHCVseroconversionthantheno-dependence
group, although the difference was not statistically sig-
niﬁcant.Itcouldbethat,becauseDUreceivingalowdose
of methadone are still surrounded by the social–medical
care network associated with the methadone therapy,
they might return more easily to a higher dose of metha-
done or call for other help in case of problems than DU
who have completely stopped methadone and are out of
the network.
The most important implication of our study is that
only when methadone is combined with provision of
needles and syringes through exchange programmes is
there a signiﬁcant reduction of HIV and HCV incidence.
Our ﬁnding is most important for countries with recent
and sometimes explosive outbreaks of HIV and/or HCV
among DU, as in the former Soviet Union and Asia
[22,23]. To provide needles and syringes only or metha-
done only will not be sufﬁcient to curb the rapid spread of
these and other blood-borne infections among DU. It is
essential to offer a comprehensive programme in which
both measures are combined, preferably also with social–
medical care and counselling.
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